Highlights for psoriatic disease research in 2013
What do Pope Francis, Edward Snowden and Stelara have in common?
They all share mention in the top newsmakers of 2013.
Of course, we at the National Psoriasis Foundation are most interested in psoriatic disease research news. So we polled several experts in our community for their psoriatic disease research highlights in 2013.
- Again, the success of IL-17 inhibitors (ixekizumab and secukinumab) and the IL-17 receptor inhibitor (brodalumab) was noted as a significant. All drugs are performing as well as, or better than, existing biologics in the market, at least in clinical trials.
- Tofacitinib, an oral drug that targets janus kinase, an enzyme linked to psoriasis inflammation, also is performing well in Phase II clinical trials.
- Several studies further examine the link between psoriasis and other related medical conditions. One study published in the Journal of the American Medical Association showed that children with psoriasis are more likely to be obese and to carry excess weight around the midsection. As a result, they are more likely to be at risk for metabolic syndrome. Another paper adds further proof to the link between psoriasis and cardiovascular disease. The paper, published in the Journal of the American Heart Association, showed that people with psoriasis are not only more likely to develop cardiovascular disease, but that the risk of developing cardiovascular disease increases with the severity of psoriasis.